Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating Neoadjuvant Ivonescimab for Resectable Head and Neck Cancer

NCT07094685 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT07094685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07094685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating Neoadjuvant Ivonescimab for Resectable Head and Neck Cancer
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
November 18, 2025
Completion date
November 1, 2030
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced head and neck squamous cell carcinoma, resectable head and neck squamous cell carcinoma, stage ii head and neck cutaneous squamous cell carcinoma, stage iii head and neck cutaneous squamous cell carcinoma, stage iv head and neck cutaneous squamous cell carcinoma